Ajanta Pharma introduced an anti-dementia drug named Memantine Hydrochloride in the US on Tuesday. The drug enables in curing dementia in all acute forms. Recently, during a filing in Bombay Stock Exchange (BSE) the wholly-owned drug consisted mandatory chemical chains through which the orally consumed medicines heals allergy.
The respective company launched two particular types, one in 5 mg form and other in 10 mg tablet forms. The drug is equivalent to Namenda generic version. NAMENDA Oral tablets contain memantine hydrochloride in a strength equivalent to 2 mg in each ml. The bio- solution also contains the following inactive ingredients: sorbitol solution (70%), methylparaben, propylparaben, propylene glycol, glycerin, natural peppermint flavour #104, citric acid, sodium citrate, and purified water. The cure should be left unattended if symptoms of confusion, illusion, hallucinations, coughing, chest pains, fever, trouble breathing, etc. occur at the time of treatment duly, immediately.
US Food Drug and Administration (USFDA) has granted permission of pending final approvals for 10 Abbreviated New Drug Application (ANDA) which includes 2 tentative approvals thus, making it total 14 ANDAs under review in the additional lot.
Ajanta Pharma witnessed a rise of stakes by 43.39% settling down to Rs. 106.31 crores in the context of net profit whereas net sales have increased by 15.29 % maintaining it at Rs. 419.20 crores in the present fiscal year of 2016-17. In BSE its shares went up by 0.89% after the announcement of USFDA approved the anti-dementia drug. It settled down to Rs. 1,574 having a Face Value of Rs. 2 per share.
Headquartered in Mumbai, the speciality pharmaceutical formulation company has an equity capital of 17.60 crores INR. US-based large-cap firm volatile trading sustained at Rs. 1,583.05 indicating a 1.40% rise in BSE on Tuesday morning.